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Purpose. Investigation of dry eye and corneal Langerhans cells (LCs) in systemic lupus erythematosus (SLE).Methods. Prospective
consecutive case series of 27 SLE patients and 27 control subjects. Dry eye was evaluated by lid-parallel conjunctival folds
(LIPCOF), Schirmer test, tear break-up time (TBUT), and ocular surface disease index (OSDI) questionnaire. In vivo investigation
of corneal LCs density and morphology (LCM) was performed with confocal corneal microscopy (Heidelberg Retina Tomograph
with Rostock Cornea Module). Results. Tear production and stability were pathological in SLE subjects compared to control
(Schirmer: 8.45± 9.82mm/5min versus 11.67± 3.21mm/5min; TBUT: 6.86± 3.53 s versus 11.09± 3.37 s). OSDI was significantly
greater in SLE patients (25.95± 17.92) than in controls (11.06± 7.18). Central LC density was greater in SLE patients (43.08± 48.67
cell/mm2) than in controls (20.57± 21.04 cell/mm2). There was no difference in the peripheral LC density (124.78± 165.39 versus
78.00± 39.51 cell/mm2). LCM was higher in SLE patients in the centre (1.43± 0.79) and in the periphery (2.89± 0.42) compared to
controls (centre: 1.00± 0.69, periphery: 2.35± 0.54). Conclusions. Significant changes in dry eye parameters and marked increase of
central LCs could be demonstrated in SLE patients. SLE alters not only the LC density but also the morphology, modifies corneal
homeostasis, and might contribute to the development of dry eye.
1. Introduction
Systemic lupus erythematosus (SLE) is a chronic systemic
autoimmune disease of unknown etiology. It can manifest
in the inflammation of various organs including skin, heart,
joints, blood vessels, liver, kidneys, and nonetheless ocular
tissues such as cornea [1, 2]. SLE is characterized by a
hypersensitive systemic inflammatory reaction in a wide
spectrum of tissues, and hence it may cause a wide range
of clinical signs and symptoms [3]. Although several scoring
systems have been validated to measure disease activity in
SLE [4, 5], no objective laboratory or clinical marker has
been identified that can reliably be used for the detection of
ongoing inflammation in correlation with clinical symptoms.
The cornea is endowed with heterogeneous populations
of immune cells including antigen-presenting dendritic cells
[6, 7]. Amongst them corneal Langerhans cells (LCs) play a
major role in corneal immune responses by activating T-cells
and participating in the maintenance of corneal homeostasis.
LCs are localized exclusively in the corneal epithelium and
residemainly in the peripheral cornea under nonpathological
circumstances [8–12]. In vivo confocal corneal microscopy
can provide an in vivo method to detect LCs in the corneal
epithelium [13–15]. Pathological conditions, various forms of
injuries [16], or minor stimuli to the cornea (such as contact
lens wear [17] or chronic use of antiglaucoma eye drops [18])
may induce LCs to undergo maturation with the formation
of dendrite-like processes [17, 18]. During this maturation
LCs migrate from the periphery to the area concerned with
further LC influx toward the central cornea [17].
Our team has recently demonstrated the presence of
activated LCs in the central cornea of rheumatoid arthritis
(RA) and ankylosing spondylitis (AS) patients [19, 20]. This
drove our attention to further investigate corneal LCs and
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the dry eye related parameters in another systemic inflamma-
tory disease, that is, SLE. Our hypothesis was that SLE alters
the ocular surface homeostasis and increases the LC density
and activation proportional to the severity of the general
inflammation and disease activity of SLE.
2. Methods
2.1. Patients. This study was a prospective controlled consec-
utive case series of 27 SLE patients and 27 age- and gender-
matched control subjects. The study has been performed in
accordance with the ethical standards laid down in the Dec-
laration of Helsinki. Written informed consent was obtained
from all subjects, and our study was reviewed and approved
by an independent ethics committee of the institution. The
inclusion criteria were the presence of SLE diagnosed and
classified according to the 1997 updated American College
of Rheumatology (ACR) criteria [21] and a negative ocular
medical history. The exclusion criteria were any known
ophthalmic disease, contact lens wear, previous injury of
the cornea, uveitis, and cataract. SLE patients with sec-
ondary Sjo¨gren’s syndrome diagnosed according to the 2002
American-European consensus criteria for Sjo¨gren’s syn-
dromewere also excluded from the study [4], since it has been
described that Sjo¨gren related hypolacrimation resulted in
severe dry eye, which itself results in significant changes in LC
density and morphology. Our study was focused on patients
with controlled SLE without known ocular symptoms.
2.2. SLE Disease Activity Evaluation. The SLE patients had
various disease durations and activities. Disease onset was
defined as the time when the patients fulfilled the criteria
for SLE. Disease duration represented the period from the
disease onset to the time of this study. Systemic lupus
erythematosus disease activity index (SLEDAI) [4, 5, 22]
score was calculated to determine disease activity for SLE on
the day of ophthalmic assessments. Patients with an SLEDAI
score of 0 were considered to be in remission, an SLEDAI
score between 1 and 8 was regarded as moderate disease
activity, and an SLEDAI score above 8 was regarded as high
disease activity.
In addition, further descriptive laboratory parameters
of general immune status, C-reactive protein (CRP) and
erythrocyte sedimentation rate (ESR), were documented, of
which we used CRP for further analysis in this study.
2.3. Evaluation ofDry Eye Parameters. Theprotocols for these
procedures have been described in great detail in our previous
works [19, 20]. Lid-parallel conjunctival folds (LIPCOF) were
determined at the temporal aspect of lower eyelid margin
according to the protocol by Pult et al. [23]. Tear produc-
tion was measured by Schirmer test strip (Haag-Streit, ref.
4701001, UK) without anaesthesia. Evaluation of tear break-
up time (TBUT) was carried out one minute after instillation
of fluorescein dye into the lower conjunctival sac. The mean
value of three consecutive measurements was interpreted
as TBUT. The subjective discomfort was evaluated with the
ocular surface disease index (OSDI) questionnaire [24].
All examinations were carried out on the right eye only
and in the same room under constant conditions.
2.4. In Vivo Confocal Corneal Microscopy. In vivo confo-
cal corneal microscopy was performed to quantify density
and determine morphology of the LCs. The Heidelberg
Retina Tomograph with Rostock Cornea Module (HRT II
RCM) (Heidelberg Engineering Inc., Heidelberg, Germany)
equipped with an inbuilt software of Heidelberg Eye Explorer
(version 1.5.10.0.) was used. The ocular surface was anaes-
thetized with topical anaesthetic eye drops (Oxybuprocaine-
Humacain 0.4%, Human Pharmaceuticals, Go¨do¨llo˝, Hun-
gary). Fixation of the patient’s eye was maintained with a
target mobile red light for the contralateral eye. A disposable
plastic cap (TomoCap; Heidelberg) was used to keep the
distance from the corneal surface to the microscope head
stable. Carbomer gel (Vidisic; Dr. Mann Pharma, Berlin,
Germany) was used as a coupling medium.
LC densities were examined both in the centre and in the
corneal periphery at 6 o’clock according to the established
examination scheme of Zhivov et al. [13, 17]. Thirty images
were taken of the right eye and the five best-focused images
were considered for the analysis in a masked fashion as
described previously (independent evaluator masked for
medical history or ophthalmological status of the patient)
[19, 20]. After identification of LCs (bright, mostly oval
or elongated particles with a diameter of up to 15 𝜇m)
and selection of the region of interest, cells were manually
marked, and the software automatically calculated cell
density (cell number/mm2). LCs morphology (LCM) was
evaluated on a 0–3 scale according to the size of the dendrites
compared to the largest diameter of cell body. The length
of all dendrites of all LCs in each image was measured with
the inbuilt caliper. A score 0 described the condition when
cornea was devoid of LCs. A score 1 was given when cells
lacked processes. A score 2 (small processes) was given if the
length of the processes did not exceed the longest diameter
of the cell body. A score 3 (long processes) was given if the
processes were longer than the largest diameter of the cell
body. The average of LCM was calculated in each of the
figures selected and was used to describe the maturation of
the LCs at both regions of the cornea.
2.5. Statistical Analysis. Statistical analysis was performed
using STATISTICA version 11.0 (StatSoft, Tulsa, OK, USA)
software. For the comparison of control and SLE groups
Mann-Whitney𝑈 test was performed. Central and peripheral
LC density and morphology values were compared applying
the Wilcoxon test. Subgroup analysis was performed with
Kruskal-Wallis andMann-Whitney tests. Fisher exact test was
applied to compare groups concerning presence or lack of LC
in the cornea. In all tests 𝑃 < 0.05 was considered significant.
3. Results
The mean age of SLE patients (𝑁 = 27, 42.8 ± 11.4 years)
was not different from the age of control subjects (𝑁 =
27, 40.4 ± 19.3 years, 𝑃 < 0,01, Mann-Whitney 𝑈 test).
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Table 1: Dry eye related parameters in different subgroups of SLE patients.
Study group LIPCOF Schirmer (mm/5min) TBUT [s] OSDI
Healthy individuals 1.24 ± 0.54(0–3)
11.67 ± 3.21
(6–16)
11.09 ± 3.37
(5–16)
11.06 ± 7.18
(0–35)
All SLE patients 1.36 ± 0.62(0–3)
8.45 ± 9.82∗
(2–40)
6.86 ± 3.53∗
(2–15)
25.95 ± 17.92∗
(4.5–7.4)
SLE patients according to
SLEDAI score
0 (29%) 1.37 ± 0.74(0–2)
7.62 ± 7.34
(0.5–20)
5.12 ± 1.55∗
(3–8)
16.82 ± 11.91
(4.54–35.71)
1–8 (60%) 1.29 ± 0.58(1–3)
9.86 ± 11.11
(0.2–40)
8.23 ± 3.78∗
(3–15)
29.64 ± 20.15∗
(9.09–70.45)
>8 (11%) 1.66 ± 0.57(1-2)
2.16 ± 0.76∗
(1.5–3.0)
3.66 ± 1.52∗
(2–5)
29.37 ± 11.06∗
(16.6–36.1)
SLE patients according to
CRP (mg/L)
≤5 (33%) 1.57 ± 0.97(0–3)
5.64 ± 5.08∗
(1–15)
5.28 ± 2.49∗
(2–10)
16.49 ± 10.52
(4.54–35.4)
>5 (67%) 1.28 ± 0.46(1-2)
9.31 ± 10.68∗
(0.2–40)
7.38 ± 3.72∗
(3–15)
29.10 ± 18.93∗
(5.55–70.45)
Data are expressed as mean ± SD. Comparisons between healthy individuals and SLE patients were made with Mann-Whitney tests. ∗𝑃 < 0.05. Subgroups
were compared to each other and to healthy individuals with Kruskal-Wallis and Mann-Whitney tests (not found, thus not marked in table).
CRP: C-reactive protein; SLE: systemic lupus erythematosus; SLEDAI: SLE disease activity index; TBUT: tear break-up time;OSDI: ocular surface disease index.
All examinations could be performed on every patient, and
no further exclusion was necessary. Male/female ratio was
identical in SLE (2/25) and control (6/21) groups (𝑃 = 0.18,
Fisher exact test). Disease duration was 10.5 ± 8.9 (min. 0.5,
max. 36) years. Disease activity was generally mild as the
mean SLEDAI score was 3.21 ± 4.34 (0–19). SLEDAI score
was zero in eight of the twenty-seven patients and only three
patients exceeded the SLEDAI score of 8 which is indicative
of a high disease activity. CRP (6.4 ± 8.3mg/L) and ESR
(27.3 ± 19.1mm/h) values revealed a controlled systemic
inflammatory status. Majority of patients (96%) were on
systemic glucocorticosteroid and chloroquine (85%) therapy;
40% received azathioprine and 22% methotrexate.
3.1. Dry Eye Parameters. Table 1 summarizes our dry eye
results. Of note, significant differences were detected in three
out of four dry eye related parameters between SLE and
control groups: Schirmer test and TBUT values were lower in
SLE patients than in controls (Mann-Whitney test, 𝑃 < 0.05),
and OSDI scores were greater in SLE patients than in control
patients (Mann-Whitney test, 𝑃 < 0.01) (Table 1).
Subgroup analysis showed that, in cases of complete
remission (SLEDAI = 0), only TBUT was lower in healthy
subjects (Mann-Whitney test, 𝑃 < 0.05), but LIPCOF,
Schirmer, and OSDI were not different from control. In mild
disease activity (SLEDAI 1–8), TBUT and OSDI, while in
high systemic activity of SLE (SLEDAI > 8), TBUT, OSDI
and Schirmer showed significant difference in comparison
to control. LIPCOF was not affected by SLEDAI. In patients
with SLEDAI> 8, extremely low tear productionwas revealed
(Schirmer 2.16 ± 0.76mm/5min), and tear film stability was
deteriorated (TBUT 3.66 ± 1.52 sec). No significant difference
in LIPCOF could be demonstrated in any subgroup. In
patients with SLEDAI > 8, extremely low tear production
was revealed (Schirmer 2.16 ± 0.76mm/5min), and tear film
stability was deteriorated (TBUT 3.66 ± 1.52 sec).
3.2. In Vivo Confocal Corneal Microscopy. Table 2 demon-
strates our confocal microscopy results with regard to the
different groups. LCs were present in the central and periph-
eral cornea of all SLE patients, while in controls only 8/27
expressed LC in the central cornea (𝑃 < 0.01, Fisher exact
test).
First we compared SLE patients to control subjects
(Mann-Whitney test). Central LC density was greater in SLE
patients than in controls (𝑃 < 0.05, Figures 1(a)-1(b)),
while there was no significant difference in the peripheral
LC density between SLE patients and controls (𝑃 = 0.213,
Figures 1(c)-1(d)). LCs resided predominantly at the level of
subbasal nerves; however in SLE patients we could identify
LCs even anterior to the nerve fibres either in the centre
and/or in the periphery (Figures 1(e)-1(f)). No LC could be
detected in stromal layers.
Examination of LC morphology revealed that not only
the density of LC but also the proportion of LCs with longer
protrusions was increased in SLE, which is firmly believed
to represent maturation and potential activity (Table 2,
Figure 1). Indeed central LCM was higher in SLE patients
compared to controls (score 1–3) (𝑃 < 0.05), where we have
seen mostly immature dendritic cells (absence of processes
and protrusions, score 0-1) in controls.
To gain a better understanding of the different factors
which might operate on the LCs we performed subgroup
analysis in the SLE group according to the following variables:
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Figure 1: In vivo confocal microscopic images of corneal dendritic (Langerhans) cells (LC). Size of all images is 400𝜇m × 400 𝜇m. Bar indi-
cates 50 𝜇m. Simple arrow indicates LCwithout dendrite (LCM score = 1, probably immature), double arrow corresponds with LCM score = 2
(dendrite not longer than cell body), and triple arrow demonstrates LC with long dendrites (LCM score = 3, dendrite longer than cell body,
sign of activation). Arrowhead points to subepithelial nerve plexus. (a) Image of the central cornea of a healthy volunteer. Note the normal
subepithelial nerves. No LC is visible in the centre of the cornea (LCM score = 0) (depth of image from surface 43𝜇m). (b) Central cornea
of a patient with SLE. Density of LCs is larger than that in normal corneas. Most of the LCs are of LCM score 1, but some are of LCM score
2 (depth of image from surface 48𝜇m). (c) Peripheral cornea of the same control eye as in Figure 1(a). Note that some LCs can be observed
(only of LCM score 1). (d) Peripheral corneal image of the same patient as in Figure 1(b). Mixed population of LCs of LCM scores 1 and 3 can
be seen (depth of image from surface 46 𝜇m). (e) Image taken anteriorly from subepithelial nerve fibres (37𝜇m from surface) of the central
cornea of an SLE patient. A large number of LCs are of LCM score 3 and some are of LCM score 1. (f) Peripheral cornea of the same patient
as in Figure 1(e) (36 𝜇m from the surface). Density of LCs (predominantly LCM Score 3) is larger than that in the centre of the same cornea.
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Table 2: Confocal microscopy results in different subgroups of SLE patients.
Study group LC centr. (cell/mm2) LC periph. (cell/mm2) LCM centr. LCM periph.
Healthy individuals 20.57 ± 21.04(0–71)
78.00 ± 39.51
(26–223)
1.00 ± 0.69
(0–3)
2.35 ± 0.54
(0–3)
All SLE patients 43.08 ± 48.67
∗
(1–169)
124.78 ± 165.39
(19–914)
1.43 ± 0.79∗
(0–3)
2.89 ± 0.42∗
(0–3)
SLE patients according to
SLEDAI score
0 (29%) 45.84 ± 43.1
∗
(1.8–125)
195.1 ± 292.9
(38.7–914)
1.63 ± 0.91
(1–3)
2.87 ± 0.35∗
(2-3)
1–8 (60%) 41.26 ± 49.35(2–169)
90.19 ± 64.76
(19–277)
1.41 ± 0.71∗
(0–3)
2.88 ± 0.48∗
(1–3)
>8 (11%) 46.10 ± 76.99
∗
(1–135)
133.20 ± 73.44
(48–179)
1.00 ± 1.00
(0–2)
3.00 ± 0.00∗
(3-3)
SLE patients according to CRP
(mg/L)
≤5 (75%) 39.96 ± 50.20(1.8–169)
135.6 ± 188.90
(19.8–914)
1.57 ± 0.81∗
(0–3)
2.86 ± 0.48∗
(1–3)
>5 (25%) 52.43 ± 46.03
∗
(1–135)
92.31 ± 50.09
(35–171)
1.00 ± 0.57
(0–2)
3.00 ± 0.00∗
(3-3)
SLE patients according to
Schirmer test (mm/5min)
<10 (61%) 42.03 ± 42.62(1–135)
147.37 ± 204.04
(35–914)
1.58 ± 0.87
(0–3)
2.91 ± 0.24∗
(2-3)
≥10 (39%) 44.68 ± 59.01
∗
(1.8–169)
89.85 ± 70.92∗
(19.8–277.3)
1.18 ± 0.60∗
(0–2)
2.81 ± 0.60∗
(1–3)
Data are expressed as mean ± SD. Comparisons between healthy individuals and SLE patients were made with Mann-Whitney tests. ∗𝑃 < 0.05. Subgroups
were compared to each other and to healthy individuals with Kruskal-Wallis and Mann-Whitney tests (not found, thus not marked in table).
CRP: C-reactive protein; SLE: systemic lupus erythematosus; SLEDAI: SLE disease activity index.
SLEDAI, CRP, and Schirmer test. In patients with high
systemic activity of SLE (SLEDAI> 8), central LC density was
46.10±76.99 cell/mm2 andperipheral LCdensitywas 133.20±
73.44 cell/mm2. The mean peripheral LCM in SLEDAI >
8 was 3.0, which means that all LCs displayed elongated
dendrites, revealing a high level of activity. In some cases
these activated LCs formed a network (Figure 2). We found
that the central LC density was greater in SLE patients when
the CRP was above 5mg/L, compared to control subjects, but
LC number was comparable to controls in SLE patients with
lower inflammatory reactions (CRP < 5mg/L). No significant
difference was detected between the CRP determined sub-
groups. Subgroup analysis of SLE patients with compromised
tear production (dry eye: Schirmer < 10mm/5min) and
nondry eye (Schirmer ≥ 10mm/5min) revealed that all LC
parameters (central and peripheral density and central and
peripheral morphology) were pathological in SLE patients
with lower tear production in comparison to controls. No
difference was found between the subgroup of SLE patients
with normal tear production and control subjects in the LC
density and central LCM values; only peripheral LCM was
higher in SLE patients with normal tear production than in
control subjects.
We also compared the central cornea to the peripheral
cornea in both controls and SLE patients (Wilcoxon test).
The peripheral LC density was greater in the periphery than
50𝜇m
Figure 2: In vivo confocal microscopic image of corneal dendritic
(Langerhans) cells (LC). Original size of the image is 400𝜇m
× 400 𝜇m. Bar indicates 50 𝜇m. Network of activated LCs with
dendrites in an extreme large density in the central cornea of an SLE
patient (depth of image from surface 41𝜇m).
in the centre in SLE patients and in the control group (𝑃 <
0.001). LCM showed more than twofold higher values in the
periphery than in the centre in controls and SLE (Table 2,
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Figure 3: Diagram of the corneal Langerhans cell density in the
central and peripheral areas. Centrally significantly greater value
was shown in patients with SLE than in control group (∗𝑃 < 0.05,
Mann-Whitney test), but therewas no significant difference between
SLE and control group in the periphery. Note the difference between
central and peripheral densities both in controls and in patients with
SLE (∗∗𝑃 < 0.05 difference, Wilcoxon test).
𝑃 < 0.001). Figure 3 summarizes central and peripheral LC
densities in SLE patients and healthy volunteers.
4. Discussion
Ophthalmic manifestations of SLE have been widely dis-
cussed in the literature; however the majority of SLE patients
do not develop ocular inflammatory symptoms throughout
the course of their illness [25–27]. Ocular surface dendritic
cells have been examined in many ophthalmic and systemic
diseases including Sjo¨gren’s syndrome, RA, and AS [14, 19,
20]. As inflammation plays a role in ocular surface diseases,
dendritic cells have been rediscovered as subjects of greater
attention lately. In our study a marked increase of dendritic
cells could be demonstrated by in vivo confocal corneal
microscopy in the central cornea even in the absence of
clinically manifested ocular inflammation and without over-
lapping Sjo¨gren’s syndrome. Additionally, more than half of
these LCs showed an activated phenotype with small or long
dendrites. There is no substantial evidence on correlation
between LCsmaturation and LCmorphology; however it has
been postulated that LCs with longer protrusions represent
a more activated state, presumable with more cytokine
production. The representation and distribution of LCs in
SLE were similar to RA and AS [1, 20].
The results suggest that an increased antigen-presenting
activity of LCs might operate in the cornea of SLE patients.
Theoretically, it could be a consequence of an increased
antigen supply or an intrinsically higher dendritic cell activity.
In SLE, an enhanced interferon-𝛼 production of dendritic
cells triggered by abnormal apoptotic material induces the
hyperactivity of multiple effector pathways, and it is consid-
ered as a key pathogenic feature of the disease [28]. The signs
of LC activation might be a consequence of continuous trig-
gering by the immune complex deposits [28]; however in vivo
confocal microscopy is not capable of demonstrating their
presence in the cornea. It can be explained by the limitation
of the magnification and resolution properties of the in vivo
confocal microscope used in this study. These studies also
demonstrated that recruitment and maturation of LCs can
be induced by several proinflammatory cytokines including
interleukin- (IL-) 1𝛼, tumor necrosis factor- (TNF-) 𝛼, IL-
6, IL-8, and IL-12 [29]. Both IL-1 inhibitors and anti-TNF-
𝛼 therapy and corticosteroid therapy effectively suppressed
the LC migration in vitro [29]. Indeed, deregulated cytokine
production contributes to immune dysfunction andmediates
tissue inflammation and organ damage in SLE. Inflammatory
cytokines, like type I and type II interferons and IL-6, IL-
1, and TNF-𝛼 as well as immunomodulatory cytokines like
IL-10 and transforming growth factor 𝛽 (TGF-𝛽), have been
identified as important players in SLE and are present in the
tear of dry eye patients [30].
Langerhans cells belong to a group of dendritic cells that
can manifest in different subtypes highlighting their activi-
ties. Zhivov et al. [13, 17] provided a confocal microscopic
(in vivo) subtype definition which was further ameliorated
and scored and applied in our present study similar to
our previous works. Ex vivo, Hamrah et al. performed
PCR, immunohistochemistry, and flow cytometry to further
investigate LCs [8]. They have shown that Langerin (a c-
type lectin expressed by specific dendritic cell populations
which recognizes glycosylated patterns on pathogens) is
specific for the LCs in corneal epithelium, whereas in corneal
stroma different types of dendritic cells participate in antigen
presentation.
Pathophysiological theories suggested and basic science
research proved that, in aqueous deficiency states such as
Sjo¨gren’s syndrome, reduced hydration of the ocular surface
may initiate or contribute to the development of dry eye by
increasing apoptosis and further induction of proinflamma-
tory cytokines including IL-1, IL-6, IL-8, and TNF-𝛼 [30].
The accumulated cytokines have the capacity to decrease
tear production via neuronal and hormonal effects [31].
Cordero-Coma et al. showed that, taking control of the
underlying systemic inflammatory disease, tear production
can improve which further supports our theory [32]. The
possible higher concentration of cytokines in the tears of
SLE patients might indirectly impair tear production and
it might partly explain the dry eye mechanism without
the presence of a true overlapping Sjo¨gren’s syndrome. Our
results are in concordance with Villani’s [33] data suggesting
that the alterations of cornea are associated with the systemic
inflammatory effect of the autoimmune disease.
The prevalence of sicca symptoms in autoimmune dis-
ease such as SLE has been reported as 36% in a study
by Wangkaew et al. [25] and 28% by Gilboe et al. [22].
Our study demonstrated that ocular sicca symptoms are
usually underdiagnosed in clinical practice. No patient had
marked dry eye complaints, but significant changes in dry
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eye parameters could be identified in our study. A majority
of our patients were females, which is in concordance with
the gender-dependent nature of SLE. Previous studies found
that SLE affects womenmore thanmen [34], and dry eye itself
is more prevalent in women than in men [35], which shaped
our intention to match the gender ratio of the control group.
It has been postulated that corneal immune status is
interrelated with dysfunctional tear production, but the
exact causative relationship is still not known in detail.
The current study could not provide exact evidence on the
relationship between LC density and dry eye parameters,
but it could be demonstrated that both activated antigen-
presenting cells and dry eye are detectable even in well
controlled SLE patients. This lack of a direct correlation
may partly be explained by the immune privileged status of
the cornea. Another explanation could be that patients in
our study were well controlled (were on complete or partial
systemic immunosuppression) with low SLEDAI index, and
we excluded patients with secondary Sjo¨gren’s syndrome.
Our results allow us to conclude that SLE alters LC
density and morphology; it subsequently modifies corneal
homeostasis and might contribute to the development of dry
eye. Increased corneal LC density might be interpreted as
an indicator of increased surveillance activity of the innate
immune system. Our hypothesis that characterization of
LC density and morphology in SLE patients could serve
as a potential biomarker of disease activity in SLE patients
with various disease severity needs further evidence to be
proved. LC density alone could not be a descriptor of disease
severity since SLE is a multifactorial disease and one param-
eter in itself probably cannot exactly describe all aspects
of the disease. The autoimmune diseases and subsequent
systemic therapies interfere with corneal homeostasis and
undoubtedly play a role in LC maturation and kinetics. The
limitation of our study is that our SLE patients were on
systemic immunosuppressive treatment, resulting in con-
trolled systemic inflammation. Investigation of therapy-naive
SLE patients with more pronounced systemic inflammation
would also be interesting.
Further investigations are required to clarify the role of
adaptive immunity in the cornea in systemic inflammatory
rheumatic diseases and the connection between the dry eye
mechanism, the systemic inflammation, and the LCs.
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